Compare XENE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | CRSP |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2014 | 2016 |
| Metric | XENE | CRSP |
|---|---|---|
| Price | $59.75 | $55.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $68.55 | ★ $70.29 |
| AVG Volume (30 Days) | 621.9K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $311,000.00 | ★ $289,590,000.00 |
| Revenue This Year | N/A | $807.72 |
| Revenue Next Year | $2,496.48 | $172.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $35.60 | $44.12 |
| 52 Week High | $72.66 | $78.48 |
| Indicator | XENE | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 52.29 |
| Support Level | $52.40 | $50.45 |
| Resistance Level | $62.91 | $59.94 |
| Average True Range (ATR) | 2.20 | 2.72 |
| MACD | -0.22 | -0.25 |
| Stochastic Oscillator | 17.95 | 41.78 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.